person · Reporting owner

Johnson Craig A

Disclosed activity across 5 companies

Tapewire entity: 40405
SEC CIK: 0001370348

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aurinia Pharmaceuticals Inc.AUPH · Entity 4463	Director	June 04, 2026	June 08, 2026
HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133	Director	January 30, 2026	February 03, 2026
Odonate Therapeutics, Inc.ODT · Entity 132524	Director	December 29, 2020	December 31, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aurinia Pharmaceuticals Inc.

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.67 · Expires 2036-06-04	Direct	23,931	Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 23,931 · Balance 23,931 F1: The options shall vest one year from date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The options shall vest one year from date of grant.

HERON THERAPEUTICS, INC. /DE/

Report date January 30, 2026 · Filed February 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	53,960	Reported balance After 2026-01-30 transaction · row 1 1 source row Row 1 · 2026-01-30 · Grant · Acquired 53,960 · Balance 53,960 F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.

Odonate Therapeutics, Inc.

Report date December 29, 2020 · Filed December 31, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,000	Reported balance After 2020-12-29 transaction · row 1 1 source row Row 1 · 2020-12-29 · Purchase · Acquired 3,000 · Balance 3,000 F1: These shares were acquired through the open market.

Filing footnotes · ownership attribution and instrument terms

F1: These shares were acquired through the open market.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

LA JOLLA PHARMACEUTICAL CO

Report date August 22, 2022 · Filed August 24, 2022

Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-08-22 transaction · row 1 1 source row Row 1 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00	Direct	Reported balance After 2022-08-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-08-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.84	Direct	Reported balance After 2022-08-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-08-22 · Disposition to issuer · Disposed 19,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.69	Direct	Reported balance After 2022-08-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.24	Direct	Reported balance After 2022-08-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.19	Direct	Reported balance After 2022-08-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.10	Direct	Reported balance After 2022-08-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.99	Direct	Reported balance After 2022-08-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.25	Direct	Reported balance After 2022-08-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53	Direct	Reported balance After 2022-08-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81	Direct	Reported balance After 2022-08-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.

Mirati Therapeutics, Inc.

Report date January 23, 2024 · Filed January 24, 2024

Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2024-01-23 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2024-01-23 · Disposition to issuer · Disposed 6,021 · Balance 11,252 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 4,444 · Balance 6,808 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Row 3 · 2024-01-23 · Disposition to issuer · Disposed 6,808 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $15.72 · Expires 2026-05-17	Direct	Reported balance After 2024-01-23 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-01-23 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.54 · Expires 2024-09-08	Direct	Reported balance After 2024-01-23 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-01-23 · Disposition to issuer · Disposed 18,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2028-01-17	Direct	Reported balance After 2024-01-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-01-23 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20	Direct	Reported balance After 2024-01-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-01-23 · Disposition to issuer · Disposed 7,520 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $64.14 · Expires 2029-01-16	Direct	Reported balance After 2024-01-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-01-23 · Disposition to issuer · Disposed 11,000 · Balance 0 F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.

F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.

F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.

F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.

F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

F6: Pursuant to the Merger Agreement, at the Effective Time, each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a Per Share Exercise Price that was equal to or greater than the Closing Consideration, but was less than the sum of the Closing Consideration and the maximum amount payable in respect of one CVR (the "Maximum Total Consideration"), was cancelled and converted into the right to receive a cash payment equal to (A) the excess of (x) the sum of (i) the Closing Consideration plus (ii) the actual Milestone Payment, if any, made in respect of one CVR over (y) the Per Share Exercise Price, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

F7: Such payment will be made if, and only if, a Milestone Payment is made in respect of a CVR and will be made at the same time the Milestone Payment is made to holders of CVRs. If the CVR is terminated or expires without payment, no payment will be made with respect to any such Company Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 21, 2021 Filed Jan 25, 2021 21:31 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	3,372	$212.97	$718,151.03	Disclosure SEC source: 0001214659-21-000756 · marketforms-51235.xml · nonDerivative · entry 5 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,853 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $212.52 to $213.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 21, 2021 Filed Jan 25, 2021 21:31 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	4,562	$211.94	$966,851.58	Disclosure SEC source: 0001214659-21-000756 · marketforms-51235.xml · nonDerivative · entry 4 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,225 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $211.40 to $212.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 21, 2021 Filed Jan 25, 2021 21:31 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	3,183	$210.81	$671,004.41	Disclosure SEC source: 0001214659-21-000756 · marketforms-51235.xml · nonDerivative · entry 3 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,787 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $210.39 to $211.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 21, 2021 Filed Jan 25, 2021 21:31 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	3,505	$210.01	$736,069.63	Disclosure SEC source: 0001214659-21-000756 · marketforms-51235.xml · nonDerivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,970 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $209.37 to $210.355. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 21, 2021 Filed Jan 25, 2021 21:31 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	15,000	$20.54	$308,100.00	Disclosure SEC source: 0001214659-21-000756 · marketforms-51235.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020. Read SEC document
January 15, 2021 Filed Jan 20, 2021 23:15 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantNon Qualified Stock Option (right to buy) · Derivative	2,155	$0.00 Strike: $214.47	$0.00	Disclosure SEC source: 0001214659-21-000677 · marketforms-50980.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155 Underlying: Common Stock · 2,155 shares Expires 2031-01-14 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document
January 15, 2021 Filed Jan 20, 2021 23:15 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	1,475	$0.00	$0.00	Disclosure SEC source: 0001214659-21-000677 · marketforms-50980.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,475 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document
December 29, 2020 Filed Dec 31, 2020 21:01 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	PurchaseCommon Stock	3,000	$17.00	$51,000.00	Disclosure SEC source: 0001209191-20-065664 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · kind: These shares were acquired through the open market. Read SEC document
December 21, 2020 Filed Dec 23, 2020 21:21 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $19.46	$0.00	Disclosure SEC source: 0001209191-20-065011 · doc4.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-12-21 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
December 21, 2020 Filed Dec 23, 2020 21:21 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001209191-20-065011 · doc4.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,840 F1 · shares: The shares were granted as restricted stock units which vest in four equal quarterly installments beginning three months after the date of grant. Read SEC document
December 10, 2020 Filed Dec 14, 2020 16:20 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $4.53	$0.00	Disclosure SEC source: 0000920465-20-000163 · wf-form4_160798079024007.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document
December 08, 2020 Filed Dec 10, 2020 21:04 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $16.52	$0.00	Disclosure SEC source: 0001209191-20-062684 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
April 20, 2020 Filed Apr 21, 2020 21:26 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $25.84	$0.00	Disclosure SEC source: 0001214659-20-003604 · marketforms-48601.xml · derivative · entry 3 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document
April 20, 2020 Filed Apr 21, 2020 21:26 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	15,000	$93.00	$1,395,000.00	Disclosure SEC source: 0001214659-20-003604 · marketforms-48601.xml · nonDerivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. Read SEC document
April 20, 2020 Filed Apr 21, 2020 21:26 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	15,000	$25.84	$387,600.00	Disclosure SEC source: 0001214659-20-003604 · marketforms-48601.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2020. Read SEC document
January 09, 2020 Filed Jan 13, 2020 16:17 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $5.25	$0.00	Disclosure SEC source: 0000920465-20-000013 · wf-form4_157895025331000.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document
January 03, 2020 Filed Jan 8, 2020 01:27 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantNon-Qualified Stock Option (Right to Buy) · Derivative	4,000	$0.00 Strike: $113.20	$0.00	Disclosure SEC source: 0001214659-20-000191 · marketforms-47234.xml · derivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-01-02 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document
January 03, 2020 Filed Jan 8, 2020 01:27 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001214659-20-000191 · marketforms-47234.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document
December 20, 2019 Filed Dec 23, 2019 16:08 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $3.93	$0.00	Disclosure SEC source: 0000920465-19-000181 · wf-form4_157713531693251.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on December 20, 2020. Read SEC document
December 19, 2019 Filed Dec 23, 2019 21:24 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	23,000	$0.00 Strike: $25.02	$0.00	Disclosure SEC source: 0001209191-19-061788 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
December 10, 2019 Filed Dec 12, 2019 23:20 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $30.51	$0.00	Disclosure SEC source: 0001209191-19-060277 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-12-10 F1 · derivative.exercise_date: The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document
January 29, 2019 Filed Feb 1, 2019 00:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001214659-19-000676 · marketforms-43887.xml · derivative · entry 6 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018. F5 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document
January 29, 2019 Filed Feb 1, 2019 00:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $15.79	$0.00	Disclosure SEC source: 0001214659-19-000676 · marketforms-43887.xml · derivative · entry 5 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2023-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018. F4 · derivative.exercise_date: 1/4th of the shares subject to the Option shall vest and become exercisable on September 4, 2014, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. Read SEC document
January 29, 2019 Filed Feb 1, 2019 00:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	8,525	$61.80	$526,831.36	Disclosure SEC source: 0001214659-19-000676 · marketforms-43887.xml · nonDerivative · entry 4 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018. F3 · price: This transaction was executed in multiple trades at prices ranging from $61.44 to $62.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 29, 2019 Filed Feb 1, 2019 00:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	8,475	$61.11	$517,941.15	Disclosure SEC source: 0001214659-19-000676 · marketforms-43887.xml · nonDerivative · entry 3 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,525 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $60.43 to $61.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 29, 2019 Filed Feb 1, 2019 00:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	10,000	$3.65	$36,500.00	Disclosure SEC source: 0001214659-19-000676 · marketforms-43887.xml · nonDerivative · entry 2 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018. Read SEC document
January 29, 2019 Filed Feb 1, 2019 00:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	7,000	$15.79	$110,530.00	Disclosure SEC source: 0001214659-19-000676 · marketforms-43887.xml · nonDerivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 30, 2018. Read SEC document
January 23, 2019 Filed Jan 28, 2019 12:54 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $5.99	$0.00	Disclosure SEC source: 0000920465-19-000024 · wf-form4_154869803331636.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 23, 2020. Read SEC document
January 17, 2019 Filed Jan 23, 2019 00:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantNon-Qualified Stock Option (right to buy) · Derivative	11,000	$0.00 Strike: $64.14	$0.00	Disclosure SEC source: 0001214659-19-000455 · marketforms-43762.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document
December 31, 2018 Filed Jan 4, 2019 01:07 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $14.08	$0.00	Disclosure SEC source: 0001209191-19-001520 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-12-31 F1 · derivative.exercise_date: The stock options vest and become exercisable on December 31, 2019, subject to the Reporting Person's continued service to the Issuer through such date. Read SEC document
December 15, 2018 Filed Dec 19, 2018 01:05 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $24.97	$0.00	Disclosure SEC source: 0001209191-18-063346 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2028-12-15 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
January 18, 2018 Filed Jan 22, 2018 23:00 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $27.00	$0.00	Disclosure SEC source: 0001214659-18-000583 · marketforms-40825.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-01-17 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document
January 02, 2018 Filed Jan 5, 2018 01:54 UTC	Odonate Therapeutics, Inc. ODT · Entity 132524	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $24.73	$0.00	Disclosure SEC source: 0001209191-18-002270 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-01-02 F1 · derivative.exercise_date: This option represents a right to purchase a total of 12,500 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on January 2, 2019. Read SEC document
December 18, 2017 Filed Dec 20, 2017 21:17 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0001209191-17-066632 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2027-12-18 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
December 11, 2017 Filed Dec 13, 2017 21:06 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $28.10	$0.00	Disclosure SEC source: 0000920465-17-000081 · wf-form4_151321719471634.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-12-11 F1 · derivative.exercise_date: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, which shall be fully vested and exercisable on December 11, 2018. Read SEC document
May 17, 2017 Filed May 19, 2017 22:04 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,000	$0.00 Strike: $3.65	$0.00	Disclosure SEC source: 0001190725-17-000126 · edgardoc.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document
January 04, 2017 Filed Jan 6, 2017 18:22 UTC	LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $19.19	$0.00	Disclosure SEC source: 0000920465-17-000015 · wf-form4_148374495798908.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock which shall be fully vested and exercisable on January 4, 2018. Read SEC document
December 21, 2016 Filed Dec 23, 2016 21:06 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $13.00	$0.00	Disclosure SEC source: 0001209191-16-156663 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2026-12-21 F1 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document
October 07, 2016 Filed Oct 8, 2016 01:01 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $16.83	$0.00	Disclosure SEC source: 0001209191-16-145484 · doc4.xml · derivative · entry 1 Johnson Craig A · CIK 0001370348 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-10-07 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.